Victory Capital Management Inc. Sells 2,273 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,609 shares of the biopharmaceutical company's stock after selling 2,273 shares during the quarter. Victory Capital Management Inc. owned approximately 0.09% of Regeneron Pharmaceuticals worth $101,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Sachetta LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ REGN traded down $21.82 during mid-day trading on Thursday, hitting $782.51. 1,085,547 shares of the stock traded hands, compared to its average volume of 526,632. The stock has a fifty day moving average price of $1,000.06 and a 200-day moving average price of $1,035.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $85.99 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 3.10 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $780.95 and a 52 week high of $1,211.20.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.48% of the company's stock.

Analyst Ratings Changes

REGN has been the topic of several research analyst reports. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Finally, TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,097.14.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.